2. Search Result
Search Result
Results for "

gemcitabine

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

6

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17026
    Gemcitabine
    Maximum Cited Publications
    146 Publications Verification

    LY 188011

    		 Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis Cancer
    Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .
    Gemcitabine
  • HY-108932
    Gemcitabine monophosphate

    gemcitabine 5′-phosphate

    		 Apoptosis Cancer
    Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .
    Gemcitabine monophosphate
  • HY-130812
    Gemcitabine-O-Si(di-iso)-O-Mc

    		Drug-Linker Conjugates for ADC Cancer
    Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker .
    Gemcitabine-O-Si(di-iso)-O-Mc
  • HY-13538
    Gemcitabine elaidate
    4 Publications Verification

    CP-4126; CO-101; gemcitabine 5'-elaidate

    		 Nucleoside Antimetabolite/Analog Autophagy Apoptosis Cancer
    Gemcitabine elaidate (CP-4126) is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate exhibits anti-tumor activity .
    Gemcitabine elaidate
  • HY-13538A
    Gemcitabine elaidate hydrochloride
    4 Publications Verification

    CP-4126 hydrochloride; CO-101 hydrochloride; gemcitabine 5'-elaidate hydrochloride

    		 Nucleoside Antimetabolite/Analog Autophagy Apoptosis Cancer
    Gemcitabine elaidate (CP-4126) hydrochloride is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate hydrochloride is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate hydrochloride exhibits anti-tumor activity .
    Gemcitabine elaidate hydrochloride
  • HY-17026E
    Gemcitabine triphosphate trisodium

    dFdCTP trisodium

    		 Endogenous Metabolite Cancer
    Gemcitabine triphosphate (trisodium) is one of the two nucleoside metabolites of Gemcitabine (HY-17026) in cells. The other is active diphosphate (dFdDTP). Gemcitabine triphosphate can be used as a standard in radio-labeled probe imaging studies, to identify tumors sensitive to Gemcitabine, and to evaluate Gemcitabine uptake and retention by cells .
    Gemcitabine triphosphate trisodium
  • HY-108932A
    Gemcitabine monophosphate disodium

    gemcitabine 5′-phosphate disodium

    		 Apoptosis Cancer
    Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .
    Gemcitabine monophosphate disodium
  • HY-17026R
    Gemcitabine (Standard)

    		Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis Cancer
    Gemcitabine (Standard) is the analytical standard of Gemcitabine. This product is intended for research and analytical applications. Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .
    Gemcitabine (Standard)
  • HY-17026A
    Gemcitabine triphosphate

    dFdCTP

    		 Drug Metabolite Endogenous Metabolite Cancer
    Gemcitabine triphosphate (dFdCTP) is one of the two nucleoside metabolites of Gemcitabine (HY-17026) in cells. The other is active diphosphate (dFdDTP). Gemcitabine triphosphate can be used as a standard in radio-labeled probe imaging studies, to identify tumors sensitive to Gemcitabine, and to evaluate Gemcitabine uptake and retention by cells .
    Gemcitabine triphosphate
  • HY-B0003R
    Gemcitabine hydrochloride (Standard)

    LY 188011 hydrochloride (Standard)

    		 DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Autophagy Apoptosis Cancer
    Gemcitabine (hydrochloride) (Standard) is the analytical standard of Gemcitabine (hydrochloride). This product is intended for research and analytical applications. Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .
    Gemcitabine hydrochloride (Standard)
  • HY-B0003
    Gemcitabine hydrochloride
    Maximum Cited Publications
    146 Publications Verification

    LY 188011 hydrochloride

    		 DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Autophagy Apoptosis Cancer
    Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .
    Gemcitabine hydrochloride
  • HY-B0003S
    Gemcitabine-13C,15N2 hydrochloride

    LY 188011-13C,15N2 hydrochloride

    		 Apoptosis Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Cancer
    Gemcitabine- 13C, 15N2 (hydrochloride) is the 13C and 15N labeled Gemcitabine hydrochloride[1]. Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[2][3].
    Gemcitabine-13C,15N2 hydrochloride
  • HY-B0003A
    1'-epi Gemcitabine hydrochloride

    1'-epi LY 188011 hydrochloride

    		 Others Cancer
    1'-epi Gemcitabine hydrochloride is the isomer of Gemcitabine hydrochloride (HY-B0003), and can be used as an experimental control. Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .
    1'-epi Gemcitabine hydrochloride
  • HY-B0003AS
    (2S)-Gemcitabine-13C,15N2 hydrochloride

    		Isotope-Labeled Compounds Others
    (2S)-Gemcitabine- 13C, 15N2 (hydrochloride) is the 13C and 15N labeled (2S)-Gemcitabine hydrochloride[1].
    (2S)-Gemcitabine-13C,15N2 hydrochloride
  • HY-138253
    2′,2′-Difluorodeoxyuridine

    dFdU; 2',2'-Difluoro-2'-deoxyuridine

    		 Drug Metabolite Cancer
    2′,2′-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2′,2′-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro .
    2′,2′-Difluorodeoxyuridine
  • HY-13672
    LY2334737
    1 Publications Verification

    		 Nucleoside Antimetabolite/Analog Enterovirus Infection Cancer
    LY2334737 is an nucleoside analog and is an orally active proagent of Gemcitabine. LY2334737 exhibits inhibitory activity against enterovirus A71 (EV-A71) infection. LY2334737 has antiviral and anticancer effects .
    LY2334737
  • HY-138253R
    2′,2′-Difluorodeoxyuridine (Standard)

    		Drug Metabolite Cancer
    2′,2′-Difluorodeoxyuridine (Standard) is the analytical standard of 2′,2′-Difluorodeoxyuridine. This product is intended for research and analytical applications. 2′,2′-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2′,2′-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro .
    2′,2′-Difluorodeoxyuridine (Standard)
  • HY-160818
    MC3138

    		Sirtuin Cancer
    MC3138 is a selective SIRT5 activator. MC3138 has antitumor activity on human PDAC cells, with IC50 values of 25.4-236.9 μM. MC3138 combined with Gemcitabine (HY-17026) significantly inhibits tumor growth in mice .
    MC3138
  • HY-P5021
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)

    c(RGDfE)

    		 Biochemical Assay Reagents Cancer
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research .
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)
  • HY-10032
    PF 477736
    5 Publications Verification

    PF 00477736

    		 Checkpoint Kinase (Chk) VEGFR Src c-Fms Aurora Kinase FGFR FLT3 RET CDK Cancer
    PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a Ki of 0.49 nM, it is also a Chk2 inhibitor, with a Ki of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC50=8 (Ki), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .
    PF 477736
  • HY-113314
    AFMK

    		Endogenous Metabolite Cancer
    AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pKa of AFMK at physiological pH is 8.7. Antioxidant capacity . AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway .
    AFMK
  • HY-15883
    GNE-900

    		Checkpoint Kinase (Chk) Apoptosis Cancer
    GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC50s of 0.0011, 1.5 µM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. gemcitabine (HY-17026) and GNE-900 administration shows anti-tumor activity .
    GNE-900
  • HY-149050
    Viral polymerase-IN-1 hydrochloride

    		Influenza Virus SARS-CoV Infection
    Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC90 values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against SARS-CoV-2 infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .
    Viral polymerase-IN-1 hydrochloride
  • HY-146540
    GEM-5

    		HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Cancer
    GEM-5 is a gemcitabine-based conjugate containing a HIF-1α inhibitor (YC-1) (IC50=30 nM). GEM-5 can significantly down-regulate the expression of HIF-1α and up-regulate the expression of tumor suppressor p53. GEM-5 induces the apoptosis of A2780 cells and inhibits tumor growth .
    GEM-5
  • HY-154842
    S-Gem

    		Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis Cancer
    S-Gem is a TrxR-dependent prodrug of Gemcitabine (HY-17026) and selectively activated by TrxR. S-Gem shows less cytotoxicity compared to Gemcitabine .
    S-Gem
  • HY-100709
    ZPCK

    SL-01

    		 Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis Cancer
    ZPCK is an oral active proagent of gemcitabine that was designed for improved oral bioavailability .
    ZPCK
  • HY-100885
    Acelarin
    1 Publications Verification

    NUC-1031

    		 DNA/RNA Synthesis Cancer
    Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.
    Acelarin
  • HY-159577
    Nic-15

    		PI3K mTOR Akt Cancer
    Nic-15 (compound 4n) is an anti-constrictive agent used to antagonize the hypovascularity of pancreatic tumors. The hypovascularity allows cancer cells to adapt to the nutrient-deficient tumor microenvironment and develop drug resistance. Nic-15 can regulate the PI3K/Akt/mTOR pathway and alleviate ER stress induced by Gemcitabine (HY-17026). Nic-15 can significantly inhibit the migration and colony formation of MIA PaCa-2 and PANC-1 pancreatic cancer cells. The combination of Nic-15 and Gemcitabine can effectively solve the problem of pancreatic tumor resistance. In an in vivo xenograft model, Nic-15 can significantly enhance the efficacy of Gemcitabine .
    Nic-15
  • HY-130818
    N-(5-Hydroxypentyl)maleimide

    		ADC Linker Cancer
    N-(5-Hydroxypentyl)maleimide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as Gemcitabine-O-Si(di-iso)-O-Mc (HY-130812) ) .
    N-(5-Hydroxypentyl)maleimide
  • HY-123597
    NSC 109555

    DDUG; NCI C04808

    		 Others Cancer
    NSC 109555 is an ATP-competitive inhibitor of checkpoint kinase 2 (Chk2; IC50=200 nM in a cell-free kinase assay). It is selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK with IC50 values of 210, 6,000, 7,400, and 7,100 nM, respectively. NSC 109555 inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC50=240 nM). It inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro.2 NSC 109555 (1,250 nM) potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of reactive oxygen species (ROS) in MIA PaCa-2 cells.
    NSC 109555
  • HY-115528
    FF-10502

    		Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Cancer
    FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase α and β. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells .
    FF-10502
  • HY-145441
    GEM–IB

    		Others Cancer
    GEM–IB is the conjugate of gemcitabine (GEM)-5'-phosphate with ibandronate (IB). GEM–IB as a single agent or in combination with Docetaxel (DTX) demonstrates reduced tumor burden, preservation of the bone architecture, and improved the survival in a murine model of osteosarcoma (OS) .
    GEM–IB
  • HY-16138
    Ivaltinostat

    CG-200745

    		 HDAC MDM-2/p53 Apoptosis Cancer
    Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects .
    Ivaltinostat
  • HY-16138A
    Ivaltinostat formic

    CG-200745 formic

    		 HDAC MDM-2/p53 Apoptosis Inflammation/Immunology Endocrinology
    Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat formic induces apoptosis and has anti-tumour effects .
    Ivaltinostat formic
  • HY-145314
    TC113

    		Integrin Cancer
    TC113 is a c(RGDyK)-Based conjugate of Gemcitabine (GEM). TC113 could be internalized by A549 cells through integrin αvβ3. TC113 shows potent antiproliferative properties against WM266.4 and A549 cells .
    TC113
  • HY-163323
    AKR1C3-IN-12

    		Aldose Reductase Cancer
    AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 27 nM. AKR1C3-IN-12 enhances the efficacy of Gemcitabine and Cisplatin in bladder cancer .
    AKR1C3-IN-12
  • HY-161383
    CHK1-IN-9

    		Checkpoint Kinase (Chk) Cancer
    CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC50 value of 0.55 nM. CHK1-IN-9 can enhance the effect of DNA-damaging drugs on tumor cells. CHK1-IN-9 has synergistic anticancer effects with Gemcitabine (HY-17026) .
    CHK1-IN-9
  • HY-103367
    CHK1-IN-7

    		Checkpoint Kinase (Chk) Cancer
    CHK1-IN-7 (Compound 10c) is a potent human CHK1 inhibitor. CHK1-IN-7 shows no single agent effect, potentiates the antiproliferative effect of Gemcitabine HY-17026 in both prostate and breast cancer cell lines. CHK1-IN-7 can be used for the research of cancer .
    CHK1-IN-7
  • HY-15882
    GNE-783

    		Others Cancer
    GNE-783 is a selective CHK1 inhibitor that enhances the activity of gemcitabine. GNE-783 improves the efficacy of anti-metabolite DNA damage drugs by inactivating S-phase and G2-phase cell cycle checkpoints following DNA damage. GNE-783 selectively enhances the chemical synergy of certain drugs in different tumor types, for example, enhancing the activity of temozolomide only in melanoma cell lines .
    GNE-783
  • HY-100195
    SAR-020106
    1 Publications Verification

    		 Checkpoint Kinase (Chk) Cancer
    SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC50 of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents .
    SAR-020106
  • HY-156027
    SIRT6-IN-3

    		Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK Neurological Disease Inflammation/Immunology Endocrinology Cancer
    SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .
    SIRT6-IN-3
  • HY-P99667
    Ipafricept
    1 Publications Verification

    OMP-54F28; FZD8-Fc

    		 Wnt Cancer
    Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
    Ipafricept
  • HY-N3387
    Licoricidin

    		Apoptosis NF-κB Akt MMP Inflammation/Immunology Cancer
    Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC50=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .
    Licoricidin
  • HY-169006
    Evo312

    		Apoptosis PKC Cancer
    Evo312 is a dose-dependent inhibitor of protein kinase CβⅠ (PKCβⅠ) (IC50 is 117.34 nM). Evo312 induces PANC-GR (acquired gemcitabine-resistant PC cells) cell cycle arrest and apoptosis by inhibiting PKCβ1 protein expression. Evo312 has antiproliferative effects in pancreatic cancer cells PANC-1 and PANC-GR cells with IC50 of 0.08 μM and 0.07 μM, and in human normal pancreatic ductal epithelial cells HPDE6-c7 with IC50 of 2.95 μM. Evo312 exhibits antitumor activity in a PANC-GR cell transplantation mouse model .
    Evo312

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: